nmCRPC COE

Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer - Karim Fizazi

Details
Speaking with Alicia Morgans, Karim Fizazi discusses the final overall survival analysis of the PROSPER study in nonmetastatic castration-resistant prostate cancer. Enzalutamide has previously been shown to postpone the time to metastasis or death. Data presented at ASCO 2020 demonstrated that overall survival is significantly improved in patients receiving enzalutamide — median overall survival w...

ARAMIS Trial Demonstrates Significant Improvement in Overall Survival in nmCRPC - Neal Shore

Details
Following a presentation at the ASCO 2020 Annual Meeting, Neal Shore discusses the results of the phase III ARAMIS trial which randomized over 1,500 patients with non-metastatic castration-resistant prostate cancer to 600 mg of darolutamide orally twice daily with ADT, versus a placebo-controlled combination with ADT. The study had a composite endpoint of overall survival and radiographic progress...

Overall Survival Results of Phase III ARAMIS Study of Darolutamide Added to ADT for Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi

Details
Darolutamide is a structurally unique androgen-receptor antagonist that is approved for the treatment of prostate cancer. ARAMIS is a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant prostate cancer, and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned in a 2:1 ratio to receive daroluta...

ARAMIS Trial: Darolutamide Demonstrates Improved Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) - Fred Saad

Details
Fred Saad provides his perspective on the newest ARAMIS trial results, presented at ASCO 2020. Results from the phase III androgen receptor inhibiting agent for metastatic-free survival (ARAMIS) trial that investigated darolutamide in men with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a significant improvement in delaying the time to death in patients receiving darolutami...

Treatment Advances in Non-Metastatic Castration-Resistant Prostate Cancer - Evan Yu

Details
Evan Yu joins Alicia Morgans to discuss treatment advances in the non-metastatic castration-resistant prostate cancer space, focusing on the data and clinical implications of the ARAMIS trial. Biographies: Evan Yu, MD, Medical oncologist, treats prostate, bladder, and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies, as well as...

Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore

Details
In this conversation with Alicia Morgans, Neal Shore talks about the three new approved agents in the non-metastatic, castration-resistant prostate cancer (CRPC) setting; apalutamide, enzalutamide, and darolutamide and specifically highlight the urge for findings of prolonged survival, which have now been reported from both enzalutamide in the PROSPER trial and darolutamide in the ARAMIS trial. To...

Benefits of Early AR Targeting in Metastatic Hormone Sensitive Disease and nmCRPC - Karim Fizazi

Details
Karim Fizazi gives his insights into this evolving landscape of systemic therapies in both the non-metastatic castration-resistant and metastatic hormone-sensitive space. Dr. Fizazi discusses how therapies targeting the androgen receptor (AR) remains a critical focus in the treatment of prostate cancer. The data is showing that the introduction of these AR targeting drugs earlier in the course of...

Optimal Treatment of Newly Diagnosed Metastatic Prostate Cancer Presentation - Noel Clarke

Details
Noel Clarke presented on the optimization of the treatment of newly diagnosed metastatic prostate cancer at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Among the topics he covers in this presentation include the STAMPEDE biomedical imaging group (BIG) and STAMPEDE biomedical research group (BRG) which have incorporated 5,000 CT and bone scans with a target of more than 10,000,...

The Definition and Overview of Treatment Options in nmCRPC Presentation - Howard Scher

Details
Howard Scher presents an overview of treatment options for non-metastatic castration-resistant prostate cancer, (nmCRPC), those patients who never had detectable metastases on “conventional/standard” imaging, which includes a radionuclide bone scan and CT abdomen/pelvis +/- and MRI. These patients are generally asymptomatic from cancer itself with some symptoms from prior therapies. Importantly, t...

The Treatment of Non-Metastatic Castration-Resistant Prostate Cancer: "Pros" Presentation - Maha Hussain

Details
Maha Hussain presents during the Management of Castration-Resistant Prostate Cancer (CRPC) debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Hussain focuses on the "pros" of treating men with non-metastatic CRPC while revisiting the transformation of the field back to 2011 where stood an area of unmet need. The past 18 months have seen the reporting and FDA approval of...